Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

Immuneering Expands Board of Directors with Appointment of Ann E. Berman CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...